Fig. 4
From: Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
Analysis of p-tau217 in brain and plasma of Cohort 2. Images in (A–D) are representative pictures of CA1, where (A) shows a picture from an individual with primary age related tauopathy (PART), (B) from an individual with progressive supranuclear palsy (PSP) (non-AD tauop.), (C) from an individual with intermediate likelihood of Alzheimer’s disease (ADintermediate), and (D) from an individual with high likelihood of Alzheimer’s disease (ADhigh). Scalebar = 40 µm. Graph in (E) shows mean value (M1) of p-tau217 area in entorhinal cortex (EC), Cornu Ammonium 1 (CA1), inferior temporal gyrus (ITG), where ADhigh show significantly higher p-tau217 area compared to PART and non-AD tauop. Graph in (F) shows mean value (M2) of p-tau217 area in EC, CA1, ITG and superior frontal gyrus (SFG), where ADhigh show significantly higher compared to non-AD. Graph in (G) shows significantly higher plasma p-tau217 levels in ADhigh compared to PART, non-AD tauop and ADintermediate as well as in ADintermediate compared to PART. Scatter plotts in (H–M) show significant correlations between the p-tau217 plasma values and p-tau 217 area fraction in the EC (M), CA1 (N), ITG (O), SFG (P), M1 (Q) and M2 (R) of amyloid beta positive individuals. Each point in (E–M) represents a mean of 3 pictures from 2–3 sections (in total 6–9) from each individual and data in (E and G) was analyzed using Kruskal Wallis Test corrected for Benjamini–Hochberg False discovery rate (FDR). Data in (F) was analyzed using Mann–Whitney Test. Data in (H–M) was analyzed using Spearman correlations test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001